4.7 Article

ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression

期刊

EBIOMEDICINE
卷 71, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.ebiom.2021.103558

关键词

Epithelial ovarian cancer; Chemo resistance; ZNF711; Histone methylation; BIX-01294

资金

  1. Natural Science Foundation of China [81830082, 82030078, 91740119, 82072609, 81621004, 91740118, 82003128, 81773106, 81530082]
  2. GuangzhouScience and Technology Plan Projects [201803010098]
  3. Natural Science Foundation of Guangdong Province [2018B030311009, 2016A030308002, 2018B030311060, 2019A1515110118]
  4. Fundamental Research Funds for the Central Universities [19ykpy177]
  5. China Postdoctoral Science Foundation [2019M653220]

向作者/读者索取更多资源

ZNF711 down-regulation promotes cisplatin resistance in EOC by suppressing SLC31A1 and inhibiting CDDP influx, while ZNF711 overexpression has the opposite effect. The study provides novel therapeutic regimens for EOC treatment by targeting ZNF711-mediated mechanisms of cisplatin resistance.
Background: Resistance to platinum-based chemotherapy is a major cause of therapeutic failure during the treatment of epithelial ovarian cancer (EOC) patients. Our study aims to elucidate the molecular mechanisms by which ZNF711 down regulation promotes CISPLATIN resistance in EOC. Methods: ZNF711 expression in 150 EOC specimens was examined using immunohistochemistry. ZNF711 expression and the survival of EOC patients were assessed with a Kaplan-Meier analysis. The effects of ZNF711 expression on CDDP resistance were studied by IC50, Annexin V, and colony formation in vitro , and in an in vivo intra-peritoneal tumor model. The molecular mechanism was determined using a luciferase reporter assay, ChIP assay, CAPTURE approach, and co-IP assay. Findings: ZNF711 down-regulation exerts a great impact on CDDP resistance for EOC patients by suppressing SLC31A1 and inhibiting CDDP influx. ZNF711 down-regulation promoted, while ZNF711 over expression drastically inhibited CDDP resistance, both in vivo and in vitro . Mechanistically, the histone demethylase JHDM2A was recruited to the SLC31A1 promoter by ZNF711 and decreased the H3K9me2 level, resulting in the activation of SLC31A1 transcription and enhancement of CDDP uptake. Importantly, co-treatment with the histone methylation inhibitor, BIX-01294, increased the therapeutic efficacy of CDDP treatment in ZNF711-suppressed EOC cells. Interpretation: These findings both verified the clinical importance of ZNF711 in CDDP resistance and provide novel therapeutic regimens for EOC treatment. (C) 2021 The Authors. Published by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据